Clinical trials

Condition   Drug Name  
Study Adalimumab vs. methotrexate in psoriasis: The CHAMPION (Comparative study of HumirA vs. Methotrexate vs. Placebo In psOriasis patieNts) study
Design Randomized; Double-blind
Patients 271
Treatment Regimen Adalimumab, 80 mg s.c. --> 40 mg s.c. 1x/2 wks x 15 wks; Methotrexate, 25 [max.] mg/wk p.o. x 16 wks; Placebo
Conclusions Adalimumab was more effective than methotrexate or placebo in controlling disease and improving pain and pruritus in chronic plaque psoriasis patients
Reference(s) Improvements in psoriasis disease severity control, and pruritus with adalimumab versus methotrexate and versus placebo in patients with moderate to severe chronic plaque psoriasis: Results of the CHAMPION trial
16th Congr Eur Acad Dermatol Venereol (EADV) (May 16 2007 , Vienna) 2007:Abst P1153.
Author and Affiliation Van de Kerkhof, P., Saurat, J., Ortonne, J., Stingl, G., Mcllraith, M.